| Autor: |
Haddish‐Berhane, Nahor, Su, Yaming, Russu, Alberto, Thayu, Meena, Knoblauch, Roland E., Mehta, Jaydeep, Xie, John, Gibbs, Eric, Sun, Yu‐Nien, Zhou, Honghui |
| Předmět: |
|
| Zdroj: |
Clinical Pharmacology & Therapeutics; Mar2024, Vol. 115 Issue 3, p468-477, 10p |
| Abstrakt: |
Amivantamab has demonstrated durable responses with a tolerable safety profile in non‐small cell lung cancer with EGFR exon 20 insertions (Ex20ins) who progressed after prior platinum chemotherapy. Data supporting the amivantamab recommended phase II dose (RP2D) in this patient population are presented. Pharmacokinetic (PK) analysis and population PK (PopPK) modeling were conducted using serum concentration data obtained following amivantamab intravenous administration (140–1,750 mg). Pharmacodynamics (PDs) were evaluated using depletion of soluble EGFR and MET. Exposure‐response (E‐R) analyses were performed using the primary efficacy end point of objective response rate in patients with EGFR Ex20ins. The E‐R relationship for safety was explored for adverse events of clinical interest. Amivantamab exhibited linear PKs at 350–1,750 mg dose levels following administration, with no maximum tolerated dose identified. A two‐compartment PopPK model with linear clearance adequately described the observed PKs. Body weight was a covariate of clearance and volume of distribution in the central compartment. PopPK modeling showed that a weight‐based, 2‐tier (< 80 and ≥ 80 kg) dosing strategy reduces PK variability and provides comparable exposure across 2 weight groups, with 87% of patients achieving exposures above the target threshold. The final confirmed RP2D of amivantamab was 1,050 mg for < 80 kg (1,400 mg for ≥ 80 kg) weekly in cycle 1 (28 days) and every 2 weeks thereafter. No significant exposure‐efficacy or safety correlation was observed. In conclusion, the amivantamab RP2D is supported by PK, PD, safety, and efficacy analyses. E‐R analyses confirmed that the current regimen provides durable efficacy with tolerable safety. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text